Effects of intranasal oxytocin on emotion recognition and stress in diabetes insipidus patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of intranasal oxytocin on emotion recognition and cortisol levels in response to psychosocial stress in patients with arginine vasopressin deficiency, compared to healthy controls. The research aims to understand how oxytocin, a neuropeptide involved in social-emotional functioning, may alleviate psychological symptoms often reported by these patients despite treatment with desmopressin. Participants will receive either oxytocin nasal spray or a placebo, and their emotional responses and stress levels will be measured. The study seeks to provide insights into the potential anxiolytic and prosocial effects of oxytocin in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion criteria healthy controls

1. Adult healthy volunteers
2. Matched for age, sex, BMI, and oestrogen replacement/menopause/hormonal contraceptives to patients.
3. No medication, except hormonal contraception

Inclusion criteria

1. Adult patients with a confirmed diagnosis of AVP deficiency based on accepted criteria6
2. Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies.

Exclusion criteria

1. Participation in a trial with investigational drugs within 30 days
2. Active substance use disorder within the last six months
3. Consumption of alcoholic beverages \>15 drinks/week
4. Current or previous psychotic disorder (e.g., schizophrenia spectrum disorder)
5. Pregnancy and breastfeeding within the last eight weeks

Where it's running

• University Hospital Basel
  Basel, Switzerland Recruiting

Study contacts

• Principal investigator: Mirjam Christ-Crain, Prof. Dr. — University Hospital, Basel, Switzerland
• Study coordinator: Mirjam Christ-Crain, Prof. Dr.
• Email: mirjam.christ-crain@ubs.ch
• Phone: +41 61 328 70 80

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Copeptin test after mannitol vs hypertonic saline to diagnose PPS

  This study tests whether a mannitol-based test can diagnose the cause of polyuria-polydipsia syndrome as accurately as the current hypertonic saline test, and which method patients prefer.

  Recruiting University Hospital, Basel, Switzerland · Basel · NCT07569861

• Checking oxytocin levels in children with pituitary disease

  This pilot will test whether a single oral dose of combined estrogen/progestin boosts oxytocin release in young people with pituitary-related hormone deficiencies and matched controls.

  Recruiting Early Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07568509

• Test of NDI-5001 in adult men with X-linked nephrogenic diabetes insipidus

  This trial tests whether NDI-5001 is safe and well taken up in the body when taken as capsules by adult men with X-linked nephrogenic diabetes insipidus.

  Recruiting at 2 sites Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Santa Ana, California and 2 other locations · NCT07525960

• How oral estrogens affect blood oxytocin in healthy people and those with AVP deficiency

  This study will test whether two oral estrogens can trigger oxytocin release in healthy adults and in people with AVP-deficiency (central diabetes insipidus).

  Recruiting University Hospital, Basel, Switzerland · Basel · NCT07361263

• Intranasal oxytocin for sexual well‑being in people with arginine vasopressin deficiency and matched healthy adults

  This trial will test whether a nasal oxytocin spray can improve sexual well‑being, arousal, intimacy and related emotions in adults with arginine vasopressin deficiency and in matched healthy adults.

  Recruiting Phase 2 University Hospital, Basel, Switzerland · Basel · NCT06808516

• Lower dose radiotherapy for treating children with CNS germinoma

  This study is testing if giving a lower dose of radiotherapy after chemotherapy can effectively treat children with CNS germinomas while reducing side effects.

  Recruiting at 113 sites Phase 2 Children's Oncology Group · Mobile, Alabama and 114 other locations · NCT06368817

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.